Primary Biliary Cirrhosis Drugs Market, By Drug, And By Distribution Channel

 

Primary biliary cholangitis (PBC), formerly called primary biliary cirrhosis, is really a chronic liver disease caused by progressive destruction of the bile ducts in the liver – called the intrahepatic bile ducts.

Primary Biliary Cirrhosis Drugs Market is growing at a quicker pace with substantial growth rates throughout the last few years and is estimated that the marketplace will grow significantly in the forecasted period i.e. 2020 to 2027. The rising awareness campaigns to lessen further complications in the primary biliary cholangitis indication is one of the key factors driving the global market. Various non-profit organizations may also be operating awareness programs and funding research on novel therapies to treat the condition. This may foster market growth. The Global Primary Biliary Cirrhosis Drug Market report provides a holistic evaluation of the market. The report supplies a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Moreover, increasing FDA approvals is also likely to be major factor enhancing growth of the primary biliary cirrhosis drug market. For example, in 2016, Intercept Pharmaceuticals, Inc., received FDA approval for the Ocaliva, obeticholic acid based drug, in combination with ursodeoxycholic acid for adults with inadequate a reaction to ursodeoxycholic acid based monotherapy for treating primary biliary cirrhosis. Increasing incidence of primary biliary cirrhosis is expected to further drive growth of the primary biliary cirrhosis drugs market. Primary biliary cirrhosis occurs in patients aged 40–60 years and affects women more frequently than men.